BACKGROUND AND OBJECTIVES: An excessive inflammatory response in patients with coronavirus disease 2019 (COVID-19) is associated with high disease severity and mortality. Specific acute phase reactants might be useful for risk stratification. We conducted a systematic review and meta-analysis of studies of serum amyloid A (SAA) in patients with COVID-19.METHODS: We searched PubMed, Web of Science and Scopus, between January 2020 and December 2020, for studies reporting SAA concentrations, COVID-19 severity and survival status.RESULTS: Nineteen studies in 5,617 COVID-19 patients were included in the meta-analysis. Pooled results showed that SAA concentrations were significantly higher in patients with severe disease and non-survivors (standard mean difference, SMD, 1.20, 95% CI 0.91-1.49, P<0.001). Extreme between-study heterogeneity was observed (I2=92.4%, P<0.001). In sensitivity analysis, the effect size was not significantly affected when each study was in turn removed (range between 1.10-1.29). The Begg's (P=0.030), but not the Egger's (P=0.385), test revealed the presence of publication bias. Pooled SMD values were significantly and positively associated with gender (t=2.20, P=0.047) and aspartate aminotransferase (t=3.44, P=0.014).CONCLUSIONS: SAA concentrations were significantly and positively associated with higher COVID-19 severity and mortality. This acute phase reactant might assist with risk stratification and monitoring in this group.

Serum amyloid A concentrations, COVID-19 severity and mortality: an updated systematic review and meta-analysis / Zinellu, Angelo; Paliogiannis, Panagiotis; Carru, Ciriaco; Mangoni, Arduino A. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 105:(2021), pp. 668-674. [10.1016/j.ijid.2021.03.025]

Serum amyloid A concentrations, COVID-19 severity and mortality: an updated systematic review and meta-analysis

Zinellu, Angelo;Paliogiannis, Panagiotis;Carru, Ciriaco;
2021-01-01

Abstract

BACKGROUND AND OBJECTIVES: An excessive inflammatory response in patients with coronavirus disease 2019 (COVID-19) is associated with high disease severity and mortality. Specific acute phase reactants might be useful for risk stratification. We conducted a systematic review and meta-analysis of studies of serum amyloid A (SAA) in patients with COVID-19.METHODS: We searched PubMed, Web of Science and Scopus, between January 2020 and December 2020, for studies reporting SAA concentrations, COVID-19 severity and survival status.RESULTS: Nineteen studies in 5,617 COVID-19 patients were included in the meta-analysis. Pooled results showed that SAA concentrations were significantly higher in patients with severe disease and non-survivors (standard mean difference, SMD, 1.20, 95% CI 0.91-1.49, P<0.001). Extreme between-study heterogeneity was observed (I2=92.4%, P<0.001). In sensitivity analysis, the effect size was not significantly affected when each study was in turn removed (range between 1.10-1.29). The Begg's (P=0.030), but not the Egger's (P=0.385), test revealed the presence of publication bias. Pooled SMD values were significantly and positively associated with gender (t=2.20, P=0.047) and aspartate aminotransferase (t=3.44, P=0.014).CONCLUSIONS: SAA concentrations were significantly and positively associated with higher COVID-19 severity and mortality. This acute phase reactant might assist with risk stratification and monitoring in this group.
2021
Serum amyloid A concentrations, COVID-19 severity and mortality: an updated systematic review and meta-analysis / Zinellu, Angelo; Paliogiannis, Panagiotis; Carru, Ciriaco; Mangoni, Arduino A. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 105:(2021), pp. 668-674. [10.1016/j.ijid.2021.03.025]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/245816
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 35
social impact